Study of Alwextin® Cream in Treating Epidermolysis Bullosa

Completed · Phase 2

Conditions studied: Epidermolysis Bullosa

In brief

The purpose of this study is to determine how safe and effective allantoin 3% cream (Alwextin) is in improving the healing of recurrent skin lesions and reducing overall blistering in people with epidermolysis bullosa (EB). Allantoin 3% cream is applied topically to the entire body once daily.

Key facts

Study ID

NCT00825565

Run by

Northwestern University

People needed

8

Starts

2009-02-01

Expected to finish

2010-11-01

Last updated by the study team

2018-02-28

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• history of epidermolysis bullosa

You may not qualify if…

• use of any skin product containing allantoin for 30 days prior to enrollment

Where it is running

• Robert and Ann Lurie Children's Hospital of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.